Innovative biotech company for the industrial culture of red blood cells from stem cells
ERYPHARM has achieved a revolutionary breakthrough in the mass production of cultured red blood cells, with a view to creating a new blood transfusion product.
As a valuable addition to blood donation, this product notably aims to improve quality of life in patients with hereditary blood disorders and cancer, who require multiple transfusions.
A valuable addition to blood donation
To offset risks of shortages (epidemics, aging populations)
For greater efficacy, to improve treatment
A revolutionary process
EryPharm is paving the way for a new industrial sector to mass produce cultured red blood cells.
An innovative biological product
Cultured red blood cells fulfil all the criteria for optimum transfusion.
An experienced team
Pioneering researchers with expertise in the field, working side by side with experts in industrial process development.
Latest news (in French)
Challenges 31/03/2022 – Une néobanque fait rêver vingt fois plus que les globules rouges
Europe 1 04/10/2021 – Une technique innovante pour fabriquer du sang à la demande et faire face aux pénuries